Cargando…
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
OBJECTIVE: To compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab with no treatment in preventing hospital admission or death in higher-risk patients infected with SARS-CoV-2 in the community. DESIGN: Retrospective cohort study of non-hospitalized adult patients with CO...
Autores principales: | Evans, Andrew, Qi, Cathy, Adebayo, Jubril Omololu, Underwood, Jonathan, Coulson, James, Bailey, Rowena, Lyons, Ronan, Edwards, Adrian, Cooper, Alison, John, Gareth, Akbari, Ashley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd on behalf of The British Infection Association.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911979/ https://www.ncbi.nlm.nih.gov/pubmed/36773891 http://dx.doi.org/10.1016/j.jinf.2023.02.012 |
Ejemplares similares
-
Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022) -
Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023) -
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
por: Cegolon, Luca, et al.
Publicado: (2023) -
New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022) -
Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
por: Mazzitelli, Maria, et al.
Publicado: (2023)